Ottawa, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The global inhaled therapy in respiratory disease market size is calculated at USD 11.98 billion in 2025 and is expected to reach around USD 16.22 billion by ...
SPL84 is administered directly into the lungs where it is taken up by the cells and is expected to drive the production of fully functional CFTR proteins. The Food and Drug Administration (FDA) has ...
Glenmark Specialty SA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation.
The designation was supported by data from the multicenter, double-blind, placebo-controlled phase 3 PROMIS-I study. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation ...
The drug has been granted a Competitive Generic Therapy designation by the US FDA. Glenmark is recognized as the first ...
This means that the amount of active ingredients can be reduced and therapy durations can be shortened. In addition, precise time control with very short inhalation boli permits the focused treatment ...
The tentative approval cannot take effect because a competing product was granted market exclusivity. A new formulation of treprostinil (Yutrepia) could soon be available to patients with pulmonary ...
Please provide your email address to receive an email when new articles are posted on . Inhaled corticosteroids were associated with lower odds for mortality in patients with COPD. An eosinophil count ...
Self treatment of the respiratory tract using inhalation nebulizer. For a patient at high risk of severe Covid-19 related complications, newly released data shows that inhaled remdesivir offers the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results